Patents by Inventor Lorena Fontan Gabas
Lorena Fontan Gabas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11248007Abstract: Provided herein are compounds that inhibit MALT1, a protein whose activity is responsible for constitutive NF-?B signaling in certain cancers (e.g., activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating MALT1-related diseases and disorders (e.g., cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.Type: GrantFiled: March 8, 2018Date of Patent: February 15, 2022Assignees: Cornell University, Dana-Farber Cancer Institute, Inc.Inventors: Nathanael S. Gray, David A. Scott, John Hatcher, Ari M. Melnick, Lorena Fontan Gabas
-
Publication number: 20200385405Abstract: Provided herein are compounds that inhibit MALT1, a protein whose activity is responsible for constitutive NF-?B signaling in certain cancers (e.g., activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating MALT1-related diseases and disorders (e.g., cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.Type: ApplicationFiled: March 8, 2018Publication date: December 10, 2020Applicants: Cornell University, Dana-Farber Cancer Institute, Inc.Inventors: Nathanael S. Gray, David A, Scott, John Hatcher, Ari M. Melnick, Lorena Fontan Gabas
-
Patent number: 10711036Abstract: Provided herein are compounds of Formula (I) and pharmaceutical compositions thereof, which may be useful as MALT1 inhibitors. Also provided are for the treatment of proliferative disorders (e.g., cancer (e.g., non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, MALT lymphoma), benign neoplasm, a disease associated with angiogenesis, an autoimmune disease, an inflammatory disease, an autoinflammatory disease) by administering a compound of Formula (I).Type: GrantFiled: August 26, 2016Date of Patent: July 14, 2020Assignees: Cornell University, Dana-Farber Cancer Institute, Inc., Children's Medical Center CorporationInventors: Nathanael S. Gray, David A. Scott, John Hatcher, Spandan Chennamadhavuni, Ari M. Melnick, Lorena Fontan Gabas, Hao Wu, Qi Qiao, Guangyan Du
-
Patent number: 10689366Abstract: Provided herein are bifunctional compounds that inhibit MALT1 and/or promote targeted ubiquitination for the degradation of MALT1. In particular, provided are compounds that can bind MALT1, a protein whose activity is responsible for constitutive NF-KB signaling in certain cancers (e.g., activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)), and can assist in its degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon, VHL), which can ubiquitinate MALT1, marking it for proteasome degradation. Also provided are pharmaceutical compositions comprising the bifunctional compounds, methods of treating cancer with the bifunctional compounds, methods of promoting the degradation of MALT1, and methods of binding E3 ubiquitin ligase activity in a subject by administering a compound or composition described herein.Type: GrantFiled: October 31, 2017Date of Patent: June 23, 2020Assignees: Cornell University, Dana-Farber Cancer Institute, Inc.Inventors: Ari M. Melnick, Lorena Fontan Gabas, Nathanael S. Gray, David A. Scott, John Hatcher, Guangyan Du
-
Publication number: 20190389904Abstract: Provided herein are compounds of Formula (I) and pharmaceutical compositions thereof, which may be useful as MALT1 inhibitors. Also provided are for the treatment of proliferative disorders (e.g., cancer (e.g., non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, MALT, lymphoma), benign neoplasm, a disease associated with angiogenesis, an autoimmune disease, an inflammatory disease, an autoinflammatory disease) by administering a compound of Formula (I).Type: ApplicationFiled: August 26, 2016Publication date: December 26, 2019Applicants: Cornell University, Dana-Farber Cancer Institute, Inc., Children's Medical Center CorporationInventors: Nathanael S. Gray, David A. Scott, John Hatcher, Spandan Chennamadhavuni, Ari M. Melnick, Lorena Fontan Gabas, Hao Wu, Qi Qiao, Guangyan Du
-
Publication number: 20190263785Abstract: Provided herein are bifunctional compounds that inhibit MALT1 and/or promote targeted ubiquitination for the degradation of MALT1. In particular, provided are compounds that can bind MALT1, a protein whose activity is responsible for constitutive NF-KB signaling in certain cancers (e.g., activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)), and can assist in its degradation by recruiting an E3 ubiquitin ligase (e.g., Cereblon, VHL), which can ubiquitinate MALT1, marking it for proteasome degradation. Also provided are pharmaceutical compositions comprising the bifunctional compounds, methods of treating cancer with the bifunctional compounds, methods of promoting the degradation of MALT1, and methods of binding E3 ubiquitin ligase activity in a subject by administering a compound or composition described herein.Type: ApplicationFiled: October 31, 2017Publication date: August 29, 2019Applicants: Cornell University, Dana-Farber Cancer Institute ,Inc., Children's Medical Center CorporationInventors: Ari M. Melnick, Lorena Fontan Gabas, llkay Us, Gabriella Casalena, Nathanael S. Gray, David A. Scott, John Hatcher, Guangyan Du, Hao Wu, Qi Qiao
-
Publication number: 20180251489Abstract: Provided herein are compounds of Formula (I) and pharmaceutical compositions thereof, which may be useful as MALT1 inhibitors. Also provided are for the treatment of proliferative disorders (e.g., cancer (e.g., non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, MALT, lymphoma), benign neoplasm, a disease associated with angiogenesis, an autoimmune disease, an inflammatory disease, an autoinflammatory disease) by administering a compound of Formula (I).Type: ApplicationFiled: August 26, 2016Publication date: September 6, 2018Applicants: Cornell University Cornell Center for Technology Enterprise & Commercialization (CCTEC), Dana-Farber Cancer Institute, Inc., Children's Medical Center CorporationInventors: Nathanael S. Gray, David A Scott, John Hatcher, Spandan Chennamadhavuni, Ari M. Melnick, Lorena Fontan Gabas, Hao Wu, Qi Qiao, Guangyan Du